Offene Studien Rezidiv
| Name | Titel |
|---|---|
| BOUQUET / WO42178 | A PHASE II, OPEN-LABEL, MULTICENTER, PLATFORM STUDY EVALUATING THE EFFICACY AND SAFETY OF BIOMARKER-DRIVEN THERAPIES IN PATIENTS WITH PERSISTENT OR RECURRENT RARE EPITHELIAL OVARIAN TUMORS |
| ENGOT-Cx11 / MK-3475-A18 | A Randomized, Phase 3, Double-Blind Study of Chemoradiotherapy With or Without Pembrolizumab for the Treatment of High-risk, Locally Advanced Cervical Cancer |
| EPIK-O / CBYL719K12301 | A Phase III, multi-center, randomized (1:1), open-label, active-controlled study to assess the efficacy and safety of alpelisib (BYL719) in combination with olaparib as compared to single agent cytotoxic chemotherapy, in participants with no germline BRCA mutation detected, platinum-resistant or refractory, high-grade serous ovarian cancer |
| HELP-ER | Prospective Study of HE4 serum Level in Patients with First Relapsed Ovarian Cancer |
| NEWTON | A MULTICENTER, OPEN-LABEL PHASE II TRIAL OF A NEW CUSTOMIZED DOSING (RATIONAL ADJUSTMENT OF DOSE TO REDUCE ADVERSE REACTIONS “RADAR” DOSING) OF NIRAPARIB AS MAINTENANCE THERAPY IN PLATINUM SENSITIVE OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL RECURRENT CANCER PATIENTS. |
| PazoDoble II | Pazopanib versus Pazopanib plus Gemcitabin in Patientinnen mit rezidivierten oder metastasierten uterinen Leiomyosarkomen oder uterinen Carzinosarkomen |